Business Context and Reporting Period
This Form 8-K Current Report, dated June 14, 2017, covers Viking Therapeutics, Inc., a Delaware corporation. The filing primarily reports the entry into a Material Definitive Agreement for a registered direct offering and a concurrent private placement of warrants, with the transaction closing on June 19, 2017.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 3,749,783 shares of Common Stock and warrants to purchase 0.75 shares of Common Stock for each share purchased.
- Warrant Terms: Exercise price of $1.30 per share; exercisable from December 19, 2017, through December 19, 2022.
- Pricing: Combined purchase price of $1.15 per share and warrant package.
- Proceeds: Expected aggregate net proceeds of approximately $3.8 million after deducting placement agent fees and offering expenses.
- Placement Agent Fees: Aggregate fee of 6.25% of gross proceeds, plus reimbursement of out-of-pocket expenses capped at $30,000.
- Use of Proceeds: Research and development, working capital, and general corporate purposes.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with accredited investors and a Placement Agent Agreement with Maxim Group LLC and Roth Capital Partners, LLC. Concurrently, the Company terminated a prior Common Stock Purchase Agreement with Aspire Capital Fund, LLC, dated August 24, 2016, which had committed Aspire Capital to purchase up to $12.5 million of shares. The termination was effective June 19, 2017, and incurred no liability to the Company.
Guidance, Outlook, and Risks
The filing includes forward-looking statements regarding expected proceeds, which are subject to risks and uncertainties including the Company's financial position and market conditions. The Company has agreed to a 90-day lock-up period following the closing, during which it will not issue or announce the issuance of Common Stock or equivalents, subject to certain exceptions. The warrants are subject to a beneficial ownership limitation of 4.99% (expandable to 9.99% with notice) and are not listed on any national securities exchange.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received versus the estimated $3.8 million.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Confirm the status of the terminated Aspire Capital Fund agreement and any potential future financing commitments.
- Monitor the Company's cash burn rate to assess the sufficiency of the new proceeds for stated R&D and working capital needs.
- Check for any subsequent filings regarding the exercise of warrants or changes in the beneficial ownership limitation.